BioNTech (BNTX) Stock Forecast & Price Target

$103.76 +0.88 (+0.86%)

As of 09/4/2026 04:00 PM Eastern

Compare

BioNTech - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
1

Hold
4

Buy
14

Based on 19 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 4 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$127.44
22.82% Upside

According to the 19 analysts' twelve-month price targets for BioNTech, the average price target is $127.44. The highest price target for BNTX is $155.00, while the lowest price target for BNTX is $94.00. The average price target represents a forecasted upside of 22.82% from the current price of $103.76.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Analyst Ratings Over Time

Type	Current Forecast 9/6/25 to 9/6/26	1 Month Ago 8/7/25 to 8/7/26	3 Months Ago 6/8/25 to 6/8/26	1 Year Ago 9/6/24 to 9/6/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$127.44	$127.81	$129.56	$135.80
Forecasted Upside	22.82% Upside	36.45% Upside	51.54% Upside	20.76% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Healthcare Companies	Broader Market
Consensus Rating Score	2.74	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	22.82% Upside	928.71% Upside	14.03% Upside
News Sentiment Rating	Neutral News See Recent BNTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/31/2026	Canaccord Genuity Group 3 of 5 stars	John Newman 3 of 5 stars	Lower Target	Buy	$142.00 ➝ $136.00	+33.24%
8/5/2026	Citigroup 4 of 5 stars	Geoff Meacham 5 of 5 stars	Lower Target	Buy	$130.00 ➝ $125.00	+36.11%
7/8/2026	Morgan Stanley 3 of 5 stars	Terence Flynn 5 of 5 stars	Lower Target	Overweight	$126.00 ➝ $119.00	+26.79%
7/6/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
6/5/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeffrey Walch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
6/1/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
5/27/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Dai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$117.00 ➝ $135.00	+46.34%
5/12/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$155.00 ➝ $140.00	+50.00%
5/6/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$150.00 ➝ $140.00	+50.09%
4/27/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Burns Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$130.00	+23.27%
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
3/25/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asthika Goonewardene Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
3/17/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
3/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$116.00 ➝ $94.00	+4.49%
3/11/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Etzer Darout Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$143.00 ➝ $128.00	+39.78%
3/11/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
3/10/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
3/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$128.00	+53.10%
2/2/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$113.00	-0.66%
10/23/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$121.00 ➝ $120.00	+14.72%
11/19/2024	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cory Kasimov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$110.00 ➝ $125.00	+22.71%
10/7/2024	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$97.00 ➝ $136.00	+10.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:46 AM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 2, 2026. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

The stock is currently trading at $103.81, which is significantly below the consensus price target of $127.81, suggesting a potential upside of approximately 23% for investors who believe in the company's long-term pipeline.
BioNTech SE recently received FDA approval for its XFG-adapted COVID-19 vaccine, which is expected to provide near-term revenue stability and allow the company to continue shipping doses to meet seasonal demand.
The company has a strong balance sheet with a current ratio of 7.85 and a debt-to-equity ratio of 0.01, indicating it has ample liquidity to fund its extensive clinical trials and operations without significant financial risk.
Institutional investors are showing renewed interest, with several major funds including Flossbach Von Storch SE and Bank of America Corp DE increasing their positions in the first and second quarters of 2026.
The company has a diverse pipeline of oncology candidates, including BNT111 and BNT122, which are in Phase II trials for melanoma, providing potential future growth drivers beyond its current vaccine portfolio.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

BioNTech SE recently terminated its Phase II trial for an mRNA cancer vaccine in colorectal cancer, a move that analysts have described as a clear setback that could impact investor confidence in its oncology pipeline.
The company reported a loss of $2.53 per share in its most recent quarterly earnings, missing analyst estimates and reflecting a negative net margin of 63.54%, which indicates ongoing profitability challenges.
Revenue for the most recent quarter was $122.31 million, significantly below the analyst estimate of $180.18 million, and down 59.5% compared to the same quarter last year, suggesting a sharp decline in top-line growth.
Short interest has been increasing, with the number of shares shorted rising to 2.5 million in the most recent reporting period, indicating that a growing number of investors are betting against the stock's performance.
The company's P/E ratio is negative, reflecting its current unprofitable status, which may deter value-oriented investors who prefer companies with established earnings and positive cash flows.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $127.44, with a high forecast of $155.00 and a low forecast of $94.00.

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There is currently 1 sell rating, 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 22.82% based on their 12-month stock forecasts.

BioNTech has been rated by research analysts at Canaccord Genuity Group, Citigroup, Morgan Stanley, and Weiss Ratings in the past 90 days.

Analysts like BioNTech more than other "healthcare" companies. The consensus rating for BioNTech is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BioNTech Recommendations

MarketBeat monitors more than a dozen sources for BioNTech analyst ratings, with the most recent rating issued on 8/31/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BNTX Analyst Ratings Over Time

BNTX Analyst Recommendations By Month

BNTX Price Targets by Month

BioNTech Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

BioNTech
Bull Case

BioNTech
Bear Case

BNTX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BioNTech Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BNTX Analyst Ratings Over Time

BNTX Analyst Recommendations By Month

BNTX Price Targets by Month

BioNTech Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

BioNTech Bull Case

BioNTech Bear Case

BNTX Forecast - Frequently Asked Questions

What is BioNTech's forecast for 2026?

Should I buy or sell BioNTech stock right now?

Does BioNTech's stock price have much upside?

What analysts cover BioNTech?

Do Wall Street analysts like BioNTech more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BioNTech Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

BioNTech
Bull Case

BioNTech
Bear Case